Aardvark Therapeutics (NASDAQ:AARD) Trading Up 7.6% - What's Next?

Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) rose 7.6% on Tuesday . The stock traded as high as $7.88 and last traded at $7.66. Approximately 82,143 shares were traded during trading, a decline of 40% from the average daily volume of 135,957 shares. The stock had previously closed at $7.12.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Bank of America upped their price target on shares of Aardvark Therapeutics from $22.00 to $26.00 and gave the company a "buy" rating in a research report on Thursday, March 27th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $50.00 price target on shares of Aardvark Therapeutics in a research report on Tuesday, April 1st. Royal Bank of Canada reissued an "outperform" rating and set a $21.00 price objective on shares of Aardvark Therapeutics in a research report on Tuesday, April 1st. Finally, Morgan Stanley assumed coverage on Aardvark Therapeutics in a report on Monday, March 10th. They issued an "overweight" rating and a $29.00 target price on the stock.

Aardvark Therapeutics Stock Performance

The business's 50-day moving average price is $9.95.

Insider Transactions at Aardvark Therapeutics

In other Aardvark Therapeutics news, CFO Nelson Sun purchased 10,000 shares of the company's stock in a transaction dated Friday, February 14th. The shares were acquired at an average price of $16.00 per share, for a total transaction of $160,000.00. Following the completion of the purchase, the chief financial officer now owns 99,484 shares of the company's stock, valued at approximately $1,591,744. The trade was a 11.18 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Tien-Li Lee bought 16,542 shares of the company's stock in a transaction on Friday, February 14th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $264,672.00. Following the transaction, the chief executive officer now owns 1,496,175 shares in the company, valued at $23,938,800. The trade was a 1.12 % increase in their position. The disclosure for this purchase can be found here.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.